|
An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease
|
|
W24-009-1
|
|
An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease
|
|
Dr. Biree Andemariam
|
|
The purpose of this study is to assess how orally administered Epeleuton capsules are processed in the body, how Epeleuton targets aspects of the disease and how well Epeleuton is tolerated in in patients with Sickle Cell Disease.
If patients agree to participate and qualify for the study, they will receive Epeleuton 4g - four Epeleuton 500mg - capsules taken orally administered twice a day, i.e. eight capsules daily for 16 weeks (4 months).
|
Blood - Sickle Cell Disease
|
|
|
Check with study contact
|
|
Sasia Jones. Telephone: 860-679-7879. Email: sajones@uchc.edu
|
|
Enrolling/recruiting.
|
|
|